Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
Co-Diagnostics Reports Third Quarter 2025 Financial Results
-
Co-Diagnostics hires Maxim Group for potential SPAC deal with CoSara unit
-
Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd
-
Co-Diagnostics closes $7 million stock offering at $0.55 per share
-
Co-Diagnostics, Inc. Announces Closing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
-
Co-Diagnostics prices $7 million stock offering at $0.55 per share
-
Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
-
Co-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit
-
Co-Diagnostics closes $3.8 million stock offering
-
Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
-
Co-Diagnostics raises $3.8 million in registered direct offering
-
Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
-
Co-Diagnostics Invited to Present at Maxim Group LLC Emerging Growth Virtual Conference
-
Maxim Group & H.C. Wainwright Analysts Confirm Co-Diagnostics (NADSAQ:CODX) Buy Rating with PTs of $20 and $29
-
Maxim Group & H.C. Wainwright Analysts Confirm Co-Diagnostics (NADSAQ:CODX) Buy Rating with PTs of $20 and $29
-
Saliva-Based Test Powered by Co-Diagnostics (NASDAQ:CODX) a Game Changer
-
Saliva-Based Test Powered by Co-Diagnostics (NASDAQ:CODX) a Game Changer
-
Co-Diagnostics (NASDAQ:CODX) Analysts Set Price Target Between $30 and $36
-
Co-Diagnostics (NASDAQ:CODX) Analysts Set Price Target Between $30 and $36
-
Co-Diagnostics, Inc. to Present at COVID-19 Virtual Conference Hosted by Maxim Group on May 27, 2020
-
Pre-Open Stock Movers 03/03: (MITO) (INO) (WIFI) Higher; (CODX) (TLRY) (KPTI) Lower (more...)
-
Maxim Group Downgrades Co-Diagnostics (CODX) to Hold
-
Co-Diagnostics (CODX) Announces Closing of $4.2 Million Registered Direct Offering Priced At-the-Market
-
Co-Diagnostics Announces Closing of $4.2 Million Registered Direct Offering Priced At-the-Market
-
Co-Diagnostics (CODX) Announces $4.2 Million Registered Direct Offering Priced At-the-Market
-
Co-Diagnostics Announces $4.2 Million Registered Direct Offering Priced At-the-Market
-
Co-Diagnostics Announces Closing of $5 Million Registered Direct Offering Priced At-the-Market
-
Co-Diagnostics (CODX) $5 Million Registered Direct Offering of Common Stock
-
Co-Diagnostics Announces $5.0 Million Registered Direct Offering Priced At-the-Market
-
Co-Diagnostics Expects New Royalty Structure to Lift Revenue and Expand Customer Base
-
Co-Diagnostics Expects New Royalty Structure to Lift Revenue and Expand Customer Base
-
Co-Diagnostics Mosquito Testing Products Generate Buzz
-
Co-Diagnostics Mosquito Testing Products Generate Buzz
-
Respected ‘Silicon Review’ lists Co-Diagnostics in 50 Fastest Growing Companies of 2019
-
Respected ‘Silicon Review’ lists Co-Diagnostics in 50 Fastest Growing Companies of 2019
-
MedTech Outlook Names Co-Diagnostics Inc as Top 10 In-Vitro Diagnostic Provider for 2019
-
MedTech Outlook Names Co-Diagnostics Inc as Top 10 In-Vitro Diagnostic Provider for 2019
-
H.C. Wainwright and Maxim Group Estimate Nearly 95% Upside for CODX
-
Maxim Group Starts Co-Diagnostics (CODX) at Buy
-
Co-Diagnostics, Inc. Announces Closing of $5.5 Million Registered Direct Offering
